John Goldman
Rheumatology · Atlanta, GANPI 1922170836
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 67.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $11,330 and has fallen 88.6% since, to $1,287 in 2025. Among rheumatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 562 payments — averaging $59.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- Johnson & Johnson$3K
- AbbVie$2K
- Novartis$953
- Pfizer$874
- UCB, Inc.$575
- plus $4K from 21 others
What the payments were for
- Consulting fees$7172%
- Speaking & faculty fees$18,20055%
- Grants$2401%
- Travel & lodging$1,0763%
- Food & beverage$12,87239%
- Education$1821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 136 | $22,423 |
| Johnson & Johnson | 70 | $2,613 |
| AbbVie | 81 | $2,144 |
| Novartis | 67 | $953 |
| Pfizer | 45 | $874 |
| UCB, Inc. | 20 | $575 |
| AstraZeneca(2 entities) | 21 | $569 |
| Lilly USA, LLC | 28 | $502 |
| E.r. Squibb & Sons, L.L.C. | 20 | $398 |
| Aurinia Pharma U.S., Inc. | 6 | $307 |
| ANI Pharmaceuticals, Inc. | 13 | $260 |
| Sobi, Inc | 10 | $244 |
| Boehringer Ingelheim | 8 | $240 |
| Janssen Scientific Affairs, LLC | 2 | $231 |
| Mallinckrodt Hospital Products Inc. | 6 | $185 |
| Radius Health, Inc. | 3 | $171 |
| GSK | 9 | $170 |
| Argenx US, Inc. | 1 | $137 |
| Genentech USA, Inc. | 5 | $95 |
| Bristol Myers Squibb | 4 | $85 |
| Invivyd Inc | 1 | $22 |
| Sanofi | 1 | $20 |
| Merck | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,287 in reported general payments places this provider in the 90th percentile of 177 rheumatology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel MiniEtanercept | 11 | $81,059 |
| Humira(Cf)Adalimumab | 12 | $80,754 |
| Hydroxychloroquine Sulfate | 14 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $2,144 | $80,75412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Atlanta
- Gary MyersonAtlanta$1M
- William WilsonAtlanta$344K
- Paul SutejAtlanta$140K
- Sung LimAtlanta$125K
- Arezou KhosroshahiAtlanta$66K
- Kimberley WilsonAtlanta$41K
- Wambui MachuaAtlanta$31K
- Paula TanasaAtlanta$31K
- Rattandeep SinghAtlanta$20K
- Elizabeth ButlerAtlanta$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.